# Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes

> **NCT03159052** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 450 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** SHR3824
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03159052
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06
- **Primary completion:** 2018-10
- **Final completion:** 2019-06
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2017-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03159052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03159052, "Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03159052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*